BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BRAINSTORM CELL THERAPEUTICS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026
- Market cap
- $8.50M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Dec 31, 2025, from 13F filings
Held by institutions
0.0%
0M of 11M shares
Institutional holders
0
0 new, 5 sold out
Net institutional buying
-0M
In Q4 2025
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 717,500 | 9.99% | 13G (passive) | Mar 31, 2025 |
| Kevin D. Ness | 3,060,000 | 6.25% | 13G (passive) amendment | Feb 12, 2024 |
| Matthew J. Ruck | 275,838 | 5.18% | 13G (passive) | Nov 13, 2024 |
Top institutional holders
13F holdings as of Sep 30, 2025
| Holder | Shares | % of BCLI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Osaic Holdings, Inc. | 1,785 | 0.02% | $1.35K | – | 0.00% |
| Bangor Savings Bank | 266 | 0.00% | $188 | – | 0.00% |
| VSM Wealth Advisory, LLC | 120 | 0.00% | $85 | – | 0.00% |
| Steward Partners Investment Advisory, LLC | 113 | 0.00% | $80 | – | 0.00% |
| St Germain D J Co Inc | 33 | 0.00% | $23 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q4 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 5 | 0M | 0M |
| Q3 2025 | 5 | 0M | 0.0% | 0 / 0 | 0 / 29 | 0M | 0M |
| Q2 2025 | 34 | 0M | 3.6% | 7 / 4 | 3 / 5 | 0M | 1M |
| Q1 2025 | 32 | 1M | 9.3% | 7 / 7 | 3 / 6 | 1M | 0M |
| Q4 2024 | 31 | 0M | 3.3% | 28 / 0 | 3 / 1 | 0M | 0M |
| Q3 2024 | 4 | 0M | 1.4% | 4 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Peter Joe Pitts | Executive Chairman, Director | – | – | Jul 28, 2026 |
| Uri Yablonka | EVP & Chief Business Officer, Director | 218,464 | 1.98% | May 29, 2026 |
| Alla Patlis | See Remarks | 144,349 | 1.31% | May 29, 2026 |
| Chaim Lebovits | President & CEO | 2,134,349 | 19.34% | May 29, 2026 |
| Jacob A. Frenkel | Director | 343,777 | 3.12% | Jul 28, 2026 |
| Irit Arbel | Director | 161,054 | 1.46% | May 29, 2026 |
| Ibrahim B. Dagher | Director | 79,515 | 0.72% | May 20, 2026 |
| Nir Naor | Director | 31,465 | 0.29% | May 20, 2026 |
| Anthony J. Polverino | Director | 25,730 | 0.23% | May 20, 2026 |
| Menghisteab Bairu | Director | 24,000 | 0.22% | May 20, 2026 |
| Hartoun Hartounian | Director | 52,000 | 0.47% | May 20, 2026 |
| Stacy Lindborg | Director | 48,229 | 0.44% | May 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jacob A. Frenkel Director | Jul 24, 2026 | Award | +100,000 | – | – | 343,777 |
| Chaim Lebovits President & CEO | Feb 26, 2026 | Award | +1,800,000 | – | – | 2,000,960 |
| Alla Patlis See Remarks | Feb 26, 2026 | Award | +100,000 | – | – | 144,349 |
| Irit Arbel Director | Feb 26, 2026 | Award | +120,000 | – | – | 161,054 |
| Uri Yablonka EVP & Chief Business Officer, Director | Feb 26, 2026 | Award | +150,000 | – | – | 218,464 |
| Jacob A. Frenkel Director | Feb 26, 2026 | Award | +200,000 | – | – | 243,777 |
| Ibrahim B. Dagher Chief Medical Officer | Jan 1, 2025 | Award | +50,000 | – | – | 66,849 |
| Anthony J. Polverino Director | Jan 1, 2025 | Award | +24,000 | – | – | 25,730 |
| Alla Patlis See Remarks | Jan 1, 2025 | Award | +40,000 | – | – | 44,349 |
| Jacob A. Frenkel Director | Jan 1, 2025 | Award | +40,000 | – | – | 43,777 |
| Menghisteab Bairu Director | Jan 1, 2025 | Award | +24,000 | – | – | 24,000 |
| Nir Naor Director | Jan 1, 2025 | Award | +30,666 | – | – | 31,465 |
| Stacy Lindborg Director | Jan 1, 2025 | Award | +20,000 | – | – | 48,229 |
| Uri Yablonka EVP & Chief Business Officer, Director | Jan 1, 2025 | Award | +20,000 | – | – | 68,464 |
| Uri Yablonka EVP & Chief Business Officer, Director | Jan 1, 2025 | Award | +40,000 | – | – | 48,464 |
| Irit Arbel Director | Jan 1, 2025 | Award | +30,666 | – | – | 41,054 |
| Chaim Lebovits President & CEO | Jan 1, 2025 | Award | +120,000 | – | – | 200,960 |
| Hartoun Hartounian EVP, Chief Operating Officer | Jan 1, 2025 | Award | +50,000 | – | – | 52,000 |
| Chaim Lebovits President & CEO | Oct 1, 2024 | Buy | +1,836 | $3.43 | $6.30K | 80,960 |
| Chaim Lebovits President & CEO | Sep 30, 2024 | Buy | +22,000 | $0.23 | $5.06K | 1,186,865 |
| Ibrahim B. Dagher Chief Medical Officer | Jul 19, 2024 | Sale | −63,000 | $0.35 | $22.05K | 0 |
| Hartoun Hartounian EVP, Chief Operating Officer | Jun 24, 2024 | Award | +30,000 | – | – | 30,000 |
| Chaim Lebovits President & CEO | May 28, 2024 | Buy | +15,000 | $0.52 | $7.80K | 1,164,865 |
| Chaim Lebovits President & CEO | May 28, 2024 | Award | +15,000 | $0.52 | $7.80K | 1,164,865 |
| Chaim Lebovits President & CEO | May 22, 2024 | Buy | +25,000 | $0.64 | $16.00K | 1,149,865 |
| Chaim Lebovits President & CEO | May 22, 2024 | Award | +25,000 | $0.64 | $16.00K | 1,149,865 |
| Chaim Lebovits President & CEO | May 21, 2024 | Buy | +25,000 | $0.58 | $14.50K | 1,124,865 |
| Chaim Lebovits President & CEO | May 21, 2024 | Award | +25,000 | $0.58 | $14.50K | 1,124,865 |
| Chaim Lebovits President & CEO | May 13, 2024 | Buy | +10,000 | $0.49 | $4.90K | 1,099,865 |
| Chaim Lebovits President & CEO | May 13, 2024 | Award | +10,000 | $0.49 | $4.90K | 1,099,865 |
| Chaim Lebovits President & CEO | May 11, 2024 | Buy | +10,000 | $0.47 | $4.70K | 1,089,865 |
| Chaim Lebovits President & CEO | May 11, 2024 | Award | +10,000 | $0.47 | $4.70K | 1,089,865 |
| Chaim Lebovits President & CEO | May 10, 2024 | Buy | +20,000 | $0.47 | $9.40K | 1,079,865 |
| Chaim Lebovits President & CEO | May 10, 2024 | Award | +20,000 | $0.47 | $9.40K | 1,079,865 |
| Chaim Lebovits President & CEO | May 7, 2024 | Buy | +66,300 | $0.37 | $24.53K | 1,059,865 |
| Chaim Lebovits President & CEO | May 7, 2024 | Award | +66,300 | $0.37 | $24.53K | 1,059,865 |
| Chaim Lebovits President & CEO | May 6, 2024 | Buy | +135,000 | $0.38 | $51.30K | 993,565 |
| Chaim Lebovits President & CEO | May 6, 2024 | Award | +135,000 | $0.38 | $51.30K | 993,565 |
| Chaim Lebovits President & CEO | Apr 19, 2024 | Buy | +15,000 | $0.52 | $7.80K | 858,565 |
| Chaim Lebovits President & CEO | Apr 19, 2024 | Award | +15,000 | $0.52 | $7.80K | 858,565 |
| Chaim Lebovits President & CEO | Apr 18, 2024 | Buy | +115,072 | $0.53 | $60.99K | 843,565 |
| Chaim Lebovits President & CEO | Apr 18, 2024 | Award | +115,072 | $0.53 | $60.99K | 843,565 |
| Chaim Lebovits President & CEO | Apr 17, 2024 | Buy | +130,000 | $0.55 | $71.50K | 728,493 |
| Chaim Lebovits President & CEO | Apr 17, 2024 | Award | +130,000 | $0.55 | $71.50K | 728,493 |
| Stacy Lindborg Co-Chief Executive Officer | Mar 11, 2024 | Award | +241,935 | – | – | 423,435 |
| Alla Patlis See Remarks | Mar 11, 2024 | Award | +65,246 | – | – | 65,246 |
| Chaim Lebovits President & CEO | Mar 11, 2024 | Award | +305,198 | – | – | 598,493 |
| Uri Yablonka EVP & Chief Business Officer, Director | Mar 11, 2024 | Award | +109,426 | – | – | 126,969 |
| Stacy Lindborg Co-Chief Executive Officer | Sep 1, 2023 | Buy | +11,500 | $1.77 | $20.36K | 181,500 |
| Stacy Lindborg Co-Chief Executive Officer | Aug 2, 2023 | Award | +35,000 | – | – | 170,000 |
| Chaim Lebovits President & CEO | Aug 2, 2023 | Award | +31,185 | – | – | 293,295 |
| Nir Naor Director | Jun 19, 2023 | Award | +11,999 | – | – | 11,999 |
| Kirk Taylor Chief Medical Officer | May 1, 2023 | Award | +35,000 | – | – | 35,000 |
| Chaim Lebovits President & Co-CEO | Apr 20, 2023 | Award | +75,000 | – | – | 262,110 |
| Stacy Lindborg Co-Chief Executive Officer | Apr 20, 2023 | Award | +75,000 | – | – | 135,000 |
| Stacy Lindborg Co-Chief Executive Officer | Dec 7, 2022 | Award | +35,000 | – | – | 60,000 |
| Chaim Lebovits Chief Executive Officer | Sep 18, 2022 | Award | +31,185 | – | – | 187,110 |
| Ralph Dr. Kern COO and Chief Medical Officer | Mar 6, 2022 | Award | +35,885 | – | – | 223,310 |
| Anthony J. Polverino Director | Feb 1, 2022 | Award | +3,882 | – | – | 25,960 |
| Malcolm S. Taub Director | Dec 15, 2021 | Award | +12,000 | – | – | 77,332 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.